Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs — August 5, 2020

Speakers and Panelists: Affiliations and Disclosures

Neil M. Ampel, MD
Professor Emeritus of Medicine and Immunobiology, University of Arizona
Supplemental Consultant, Mayo Clinic in Arizona
President, Coccidioidomycosis Study Group
Tucson, AZ

David Angulo, MD
Chief Medical Officer
Scynexis, Inc.
Jersey City, NJ

Bridget Marie Barker, PhD
Associate Professor
Director NAU ABSL3
Pathogen and Microbiome Institute
Northern Arizona University
Flagstaff AZ

John Bennett, MD
Senior Investigator
Clinical Mycology Section
NIAID, NIH
Bethesda, MD

Janis E. Blair, MD
Consultant, Division of Infectious Diseases
Professor of Medicine
Mayo Clinic
Phoenix, AZ

Antonino Catanzaro, MD
Professor of Medicine
University of California, San Diego
La Jolla, CA
Tom M. Chiller, MD, MPHTM
Chief, Mycotic Diseases Branch
Associate Director of Global Programs
Division of Foodborne, Waterborne, and Environmental Diseases
Nation Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention
Atlanta, GA

Cheryl Dixon, PhD
Statistical Reviewer
Division of Biometrics IV (DBIV), Office of Translational Sciences (OTS)
CDER, FDA
Silver Spring, MD

Dennis M. Dixon, PhD
Chief, Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
HHS/NIH/NIAID
Bethesda, MD

Erica Easton
President
Kern Medical Foundation
Bakersfield, CA

David Engelthaler, PhD
Co-Director and Associate Professor
Pathogen Genomics Division
TGen North
Phoenix, AZ

John Farley, MD, MPH
Director
Office of Infectious Diseases (OID)
OND, CDER, FDA
Silver Spring, MD

John Galgiani, MD
Professor, University of Arizona
Colleges of Medicine, Tucson and Phoenix
Director, UA Valley Fever Center for Excellence
Director, Banner University Health Valley Fever Program
Tucson, AZ
Edward Garvey, PhD  
Consultant  
Mycovia Pharmaceuticals  
Durham, NC

Karen Higgins, Sc.D.  
Statistical Team Leader  
DBIV, OTS  
OND, CDER, FDA  
Silver Spring, MD

Susan Hoover, MD, PhD  
Infectious Disease Group and Sanford Research  
Sanford Health  
Sioux Falls, SD

William Hope, PhD  
Dame Sally Davies Chair of AMR Research  
Director, Centre of Excellence in Infectious Diseases Research  
Department of Molecular and Clinical Pharmacology  
University of Liverpool  
United Kingdom

Caroline Jjingo, MD, MPH  
Clinical Reviewer  
Division of Anti-Infectives (DAI), Office of Infectious Diseases (OID)  
OND, CDER, FDA  
Silver Spring, MD

Royce Johnson, MD  
Medical Director of Valley Fever Institute  
Chief of Infectious Disease, Department of Medicine, Kern Medical  
Adjunct Professor of Medicine, David Geffen School of Medicine at UCLA  
Bakersfield, CA

Laura Kovanda, PhD  
Senior Director, Global Development Project Leader  
Astellas Pharma Global Development, Inc.  
Northbrook, IL

David Larwood, JD  
CEO, President  
Valley Fever Solutions  
Tucson, AZ
Gareth Lewis PhD
Vice President, Specialty Brands
Mayne Pharma
Raleigh, NC

Baoying Liu, PhD, MHS
Program Officer
Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH
Bethesda, MD

Shawn Lockhart, PhD
Senior Clinical Laboratory Advisor
Senior Advisor for AMR
Mycotic Diseases Branch
Centers for Disease Control and Prevention
Atlanta, GA

Jason Moore, Pharm.D.
Clinical Pharmacology Reviewer
Division of Infectious Disease Pharmacology (DIDP)
Office of Clinical Pharmacology (OCP)
FDA/CDER/OTS
Silver Spring, MD

Sumathi Nambiar, MD, MPH
Director
DAI, OID
OND, CDER, FDA
Silver Spring, MD

Carmelle Norice-Tra, MD, PhD
Medical Officer, Bacteriology and Mycology Branch
Division of Microbiology and Infectious Diseases
NIAID, NIH
Bethesda, MD

Hanna Oltean, MPH
Zoonotic Disease Epidemiologist
Washington State Department of Health
Seattle, Washington
Elizabeth O’Shaughnessy, MD  
Clinical Reviewer  
DAI, OID  
OND, CDER, FDA  
Silver Spring, MD

Luis Ostrosky-Zeichner, MD  
Vice-Chair of Medicine  
Director of the Laboratory of Mycology Research  
McGovern Medical School  
Houston, TX

Elektra Papadopoulos, MD, MPH  
Associate Director  
Clinical Outcome Assessments Staff  
OND CDER, FDA  
Silver Spring, MD

Peter Pappas, MD  
Professor of Medicine  
Medicine/Infectious Diseases Department  
University of Alabama  
Birmingham, AL

Thomas Patterson, MD  
Vice-Chair for Faculty Development  
Chief, Division of Infectious Diseases  
Professor of Medicine  
Director, San Antonio Center for Medical Mycology  
The University of Texas Health Science Center at San Antonio  
San Antonio TX

Rob Purdie  
Patient/Program Development Coordinator  
Valley Fever Institute  
Kern Medical  
Bakersfield, CA

John Rex, MD  
Chief Medical Officer & Director  
F2G, Ltd  
Manchester, UK
Lisa Shubitz, DVM  
Valley Fever Center for Excellence  
The University of Arizona  
Tucson, AZ  

David A Stevens, MD  
Professor (Emeritus) of Medicine  
Stanford University Medical School  
President of the California Institute for Medical Research  
San Jose, CA  

George Thompson, MD  
Associate Professor of Medicine  
Department of Medicine, Division of Infectious Diseases  
Department of Medical Microbiology and Immunology  
UC-Davis Medical Center  
Davis, CA  

Julie Tierney, JD  
Chief of Staff  
Office of Center Director, Center for Biologics Evaluation and Research (CBER)  
FDA  
Silver Spring, MD  

Thomas Walsh, MD, PhD  
Founding Director, Transplantation-Oncology Infectious Diseases Program  
Chief, Infectious Diseases Translational Research Laboratory  
Professor of Medicine, Pediatrics, and Microbiology & Immunology  
Weill Cornell Medicine of Cornell University and New York Presbyterian Hospital  
Henry Schueler Foundation Scholar  
Investigator of Emerging Infectious Diseases of the Save Our Sick Kids Foundation  
New York, NY  

Nathan Wiederhold, PharmD  
Professor, Pathology and Laboratory Medicine  
Director, Fungus Testing Laboratory  
University of Texas Health Science Center at San Antonio  
San Antonio, TX  

Erin Zeituni, PhD  
Preclinical Services Program Manager  
Bacteriology and Mycology Branch  
Division of Microbiology and Infectious Diseases  
NIAID, NIH  
Bethesda, MD
Lanling Zou, MD, PhD  
Bacteriology Program Officer  
Chief, Translational Sciences Section  
Bacteriology and Mycology Branch  
Division of Microbiology and Infectious Diseases  
NIAID, NIH  
Bethesda, MD

Disclosures

David Angulo is an employee of SCYNEXIS, Inc.

Bridget Marie Barker current funding from NIH, State of Arizona and Flinn Foundation.

Erica Easton is a full-time employee of Meridian Healthcare Partners, the management company for the Kern Medical Center Foundation.

David Engelthaler has a minor financial interest in the company Genestat Molecular Devices which holds the license to the FDA-authorized Valley Fever PCR diagnostic assay, which is owned wholly by Translational Genomics Research Institute, Dr. Engelthaler's employer. He is the Director of TGen North, the infectious disease branch of the non-profit Translational Genomics Research Institute.

John Galgiani is a full-time faculty member, University of Arizona College of Medicine-Tucson. He is Chairman of the Board and a significant share-holder of Valley Fever Solutions, Inc. Dr. Galgiani has a conflict of Interest management plan submitted to the University of Arizona.

Edward Garvey is a paid consultant for Mycovia Pharmaceuticals.

Royce H. Johnson is a full-time employee of Kern Medical. He has received travel expenses/honorariums for educational activities and meetings from Horizon Therapeutics. No additional disclosures

Laura Kovanda is a full-time employee of Pharma Company Astellas Pharma Global Development, Inc.

Gareth Lewis is a full-time employee and shareholder of Mayne Pharma.

Kieren Marr is founder and CEO of MycoMed Technologies. Consultant and Advisory Board member for Cidara Therapeutics and Sfinga Therapeutics. She has consulted for Amplyx Pharmaceuticals, Astellas Pharma, Advaxis, Chimerix, F2G Ltd, Genentech, Incyte Corp, Merck
& Co., OncoSec, RTI Surgical, Scynexis, Inc. and Vical. She receives authorship and editorial royalties from UpToDate and a grant from Merck.

**Rob Purdie** is a contracted employee of the Valley Fever Institute at Kern Medical.

**John Rex** is Chief Medical Officer & Director, F2G, Ltd.; Operating Partner & Consultant, Advent Life Sciences; and Expert-in-Residence, Wellcome Trust; He sits on the scientific advisory boards of Bugworks Research, Inc.; Basilea Pharmaceutica; Forge Therapeutics, Inc.; Novo Holdings; and Roche Pharma Research & Early Development; He is a shareholder in AstraZeneca Pharmaceuticals; F2G, Ltd; Advent Life Sciences; Macrolide Pharmaceuticals; and Bugworks Research, Inc.; He has received consulting fees from Phico Therapeutics; ABAC Therapeutics; Polyporph, Ltd.; Heptares Therapeutics, Ltd.; Gangagen, Ltd.; Meiji Seika Pharma; Basilea Pharmaceutica International Ltd.; Allegra Therapeutics GmbH; Forge Therapeutics, Inc.; SinSa Labs; AtoxBio; Peptilogics; F. Hoffmann-LaRoche, Ltd.; Novo Holdings; Innocoll; Vedanta; Progenity; Nosopham SA; Roivant Sciences; and Shionogi Inc.

**Lisa Shubitz** is a full-time employee of the University of Arizona. Dr. Shubitz’ support is from the National Institutes of Health as well as donor funds from the University of Arizona Foundation.

**David A. Stevens** has recently acted as a consultant to Riptide, Inc.; and recent research contracts held with Riptide, Inc.; Aridis, Inc.; Valley Fever Solutions, Inc. and Ganga Today Trust, and has received speaker fees from Pfizer China.

**George R. Thompson**, Associate Professor of Medicine has consulted for: Amplyx, Astellas, Cidara, F2G, Mayne, Vical. DSMB for Pfizer. Research support from: Amplyx, Astellas, Cidara, F2G, Gilead, Mayne, Merck, Regeneron, Vir

**Thomas Walsh** has received grants for experimental and clinical antimicrobial pharmacology and therapeutics to his institution from Allergan, Amplyx, Astellas, Lediant, Medicines Company, Merck, Scynexis, and Tetraphase and has served as consultant to Amplyx, Astellas, Allergan, ContraFect, Gilead, Leadiant, Medicines Company, Merck, Methylgene, Pfizer, and Scynexis.

**Nathan Wiederhold**, Research support (to UT Health Science Center San Antonio) from Astellas, bioMerieux, Cepheid, Covance, F2G, Sfunga, and Viamet. Advisory board member for Mayne Pharma, Speakers Bureau for Gilead.

**Luis Ostrosky-Zeichner** has received research funding and/or personal honoraria for consulting or speaking from Pfizer, Merck, Astellas, Cidara, Scynexis, F2G, Amplyx, Gilead, Therapeutics, Inc, Viracor, Octapharma, Biotoscana, Stendhal, Mayne, Takeda, RealTime labs, and Viracor.